Corient Private Wealth LLC Increases Position in Elanco Animal Health Incorporated $ELAN

Corient Private Wealth LLC lifted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 35.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 100,895 shares of the company’s stock after buying an additional 26,507 shares during the quarter. Corient Private Wealth LLC’s holdings in Elanco Animal Health were worth $2,283,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Elanco Animal Health in the first quarter worth $2,065,000. Goldman Sachs Group Inc. boosted its stake in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the period. Empowered Funds LLC grew its holdings in shares of Elanco Animal Health by 35.2% in the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after purchasing an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Elanco Animal Health by 4.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after purchasing an additional 76,408 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its stake in Elanco Animal Health by 2,006.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after buying an additional 295,651 shares during the period. 97.48% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ELAN. JPMorgan Chase & Co. lifted their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Citigroup upped their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Finally, Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $28.55.

Insider Buying and Selling at Elanco Animal Health

In related news, insider Rajeev A. Modi purchased 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the transaction, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 1.14% of the company’s stock.

Elanco Animal Health Price Performance

NYSE ELAN opened at $24.56 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The firm’s 50 day moving average price is $23.04 and its 200-day moving average price is $23.57. Elanco Animal Health Incorporated has a 52-week low of $13.39 and a 52-week high of $27.72. The company has a market cap of $12.27 billion, a PE ratio of -49.12, a P/E/G ratio of 1.61 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. Elanco Animal Health’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.